|
1
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ambudkar SV, Dey S, Hrycyna CA,
Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular,
and pharmacological aspects of the multidrug transporter. Annu Rev
Pharmacol Toxicol. 39:361–398. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer. Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yusa K and Tsuruo T: Reversal mechanism of
multidrug resistance by verapamil: Direct binding of verapamil to
P-glycoprotein on specific sites and transport of verapamil outward
across the plasma membrane of K562/ADM cells. Cancer Res.
49:5002–5006. 1989.PubMed/NCBI
|
|
5
|
Loo TW and Clarke DM: Defining the
drug-binding site in the human multidrug resistance P-glycoprotein
using a methanethiosulfonate analog of verapamil, MTS-verapamil. J
Biol Chem. 276:14972–14979. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chin KV, Ueda K, Pastan I and Gottesman
MM: Modulation of activity of the promoter of the human MDR1 gene
by Ras and p53. Science. 255:459–462. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Livak KJ and Schmittgen TD: Analysis of
relative geneexpression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cornwell MM and Smith DE: SP1 activates
the MDR1 promoter through one of two distinct G-rich regions that
modulate promoter activity. J Biol Chem. 268:19505–19511.
1993.PubMed/NCBI
|
|
9
|
Zhou G and Kuo MT: NF-kappaB-mediated
induction of mdr1b expression by insulin in rat hepatoma cells. J
Biol Chem. 272:15174–15183. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fine RL, Chambers TC and Sachs CW:
P-glycoprotein, multidrug resistance and protein kinase C. Stem
Cells. 14:47–55. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang XY and Zhu YQ:
Epigallocatechin-3-gallate suppressed the over-expression of HSP 70
and MDR1 induced by heat shock in SGC 7901. J Chemother.
20:355–360. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chin KV, Tanaka S, Darlington G, Pastan I
and Gottesman MM: Heat shock and arsenite increase expression of
the multidrug resistance (MDR1) gene in human renal carcinoma
cells. J Biol Chem. 265:221–226. 1990.PubMed/NCBI
|
|
13
|
David GL, Yegnasubramanian S, Kumar A,
Marchi VL, De Marzo AM, Lin X and Nelson WG: MDR1 promoter
hypermethylation in MCF-7 human breast cancer cells: Changes in
chromatin structure induced by treatment with 5-Aza-cytidine.
Cancer Biol Ther. 3:540–548. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yatouji S, El-Khoury V, Trentesaux C,
Trussardi-Regnier A, Benabid R, Bontems F and Dufer J: Differential
modulation of nuclear texture, histone acetylation, and MDR1 gene
expression in human drug-sensitive and -resistant OV1 cell lines.
Int J Oncol. 30:1003–1009. 2007.PubMed/NCBI
|
|
15
|
Tang PM, Chan JY, Zhang DM, Au SW, Fong
WP, Kong SK, Tsui SK, Waye MM, Mak TC and Fung KP: Pheophorbide a,
an active component in Scutellaria barbata, reverses
P-glycoprotein-mediated multidrug resistance on a human hepatoma
cell line R-HepG2. Cancer Biol Ther. 6:504–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karin M and Lin A: NF-kappaB at the
crossroads of life and death. Nat Immunol. 3:221–227. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pahl HL: Activators and target genes of
Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ueda K, Pastan I and Gottesman MM:
Isolation and sequence of the promoter region of the human
multidrug-resistance (P-glycoprotein) gene. J Biol Chem.
262:17432–17436. 1987.PubMed/NCBI
|
|
19
|
Israël A: The IKK complex, a central
regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol.
2:a0001582010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aydin C, Sanlioglu AD, Bisgin A, Yoldas B,
Dertsiz L, Karacay B, Griffith TS and Sanlioglu S: NF-κB targeting
by way of IKK inhibition sensitizes lung cancer cells to adenovirus
delivery of TRAIL. BMC Cancer. 10:5842010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View
Article : Google Scholar : PubMed/NCBI
|
